SIFCO Industries, Inc.’s (SIF) investors have been experiencing some short-term gains from the stock of late. Shares of the Cleveland, OH-based manufacturer of forgings, sub-assemblies and machined components (primarily serving the aerospace and defense, energy and commercial space markets) have surged 109.7% in the past three months compared with the industry’s 21.7% rise. The stock also outperformed the sector and the S&P 500’s 16.5% and 2.8% gains, respectively, in the same time frame.A major development ...

Key Takeaways Photronics expects Q1 revenues of $217-$225M and EPS of 51-59 cents per share.PLAB saw record high-end IC revenues, driven by U.S. and Asia demand in advanced nodes.Mainstream IC softness, geopolitical uncertainty and short backlog may weigh on results.Photronics (PLAB) is set to report its first-quarter fiscal 2026 results on Feb. 25.For the to-be-reported quarter, PLAB expects revenues between $217 million and $225 million. Non-GAAP earnings are expected to be between 51 cents and 59 cents p ...

Key Takeaways Sezzle is set to report 4Q25 results on Feb. 25, after market close.SEZL expects $128.3M in revenues, suggesting 30.6% y/y growth on engagement and product growth.Sezzle anticipates EPS of 96 cents, implying 31.5% growth, aided by strong margins and cost discipline.Sezzle Inc. (SEZL) will release fourth-quarter 2025 results on Feb. 25, after market close.SEZL has an impressive earnings surprise history. In the four trailing quarters, it surpassed the Zacks Consensus Estimate, with an average s ...

Key Takeaways NRDS is set to report 4Q25 results on Feb. 25, with revenues expected to rise 15.3% y/y.NerdWallet projects $207-$250M in Q4 revenues and $20-$24M in non-GAAP operating income.NRDS raised the 2025 adjusted EBITDA outlook to $141-$145M from the prior mentioned $106-$116M.NerdWallet, Inc. (NRDS) is scheduled to release fourth-quarter 2025 earnings on Feb. 25, after the closing bell.In the third quarter of 2025, NRDS delivered an earnings beat, supported by a robust year-over-year increase in tot ...

For the quarter ended December 2025, Domino's Pizza (DPZ) reported revenue of $1.54 billion, up 6.4% over the same period last year. EPS came in at $5.35, compared to $4.89 in the year-ago quarter.The reported revenue represents a surprise of +1.29% over the Zacks Consensus Estimate of $1.52 billion. With the consensus EPS estimate being $5.38, the EPS surprise was -0.56%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

AMC Entertainment (AMC) reported $1.29 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.4%. EPS of -$0.18 for the same period compares to -$0.18 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.28 billion, representing a surprise of +0.5%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being -$0.20.While investors scrutinize revenue and earnings changes year-over-year and how they compare with W ...

For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

For the quarter ended December 2025, Veris Residential (VRE) reported revenue of $71.31 million, up 4.7% over the same period last year. EPS came in at $0.19, compared to -$0.13 in the year-ago quarter.The reported revenue represents a surprise of +1.34% over the Zacks Consensus Estimate of $70.37 million. With the consensus EPS estimate being $0.16, the EPS surprise was +16.35%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Core Insights - Zoom Video Communications (ZM) is expected to report fourth-quarter fiscal 2026 results on February 25, with projected revenues between $1.23 billion and $1.235 billion, indicating a year-over-year growth of 4.08% [1] - Non-GAAP earnings per share are anticipated to be in the range of $1.48 to $1.49, reflecting a year-over-year increase of 4.96% [2] - The company has maintained a steady consensus estimate for earnings at $1.48 per share, with an average surprise of 8.9% over the last four quarters [2] Revenue and Earnings Expectations - The Zacks Consensus Estimate for revenue is currently pegged at $1.23 billion, aligning with the company's expectations [1] - The Earnings ESP for ZM is 0.00%, and it currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook for earnings performance [3] Business Environment and Growth Factors - Zoom is navigating a mature growth phase, leading to cautious optimism among investors [4] - The launch of AI Companion 3.0 in December 2025 and new agentic tools are expected to drive enterprise upsell activity [5] - Strategic partnerships with Oracle and NVIDIA are seen as potential growth levers, enhancing customer engagement and enterprise AI capabilities [6] Competitive Landscape and Challenges - The competitive environment remains challenging, with Microsoft Teams, RingCentral, and Cisco Webex aggressively targeting enterprise collaboration budgets [7] - ZM's net dollar expansion rate is at 98%, but online segment growth is only 2%, indicating constraints in expanding within the existing customer base [7] - The projected non-GAAP operating margin for Q4 is 38.9%, slightly down from 41.2% in the previous quarter, suggesting near-term profitability pressure [7] Investor Sentiment - Given the modest growth trajectory and limited near-term catalysts, investors may consider holding existing positions or waiting for a more favorable entry point before increasing exposure [8][9]

Key Takeaways Roche's FDA filing for giredestrant in ER-positive breast cancer accepted, with a Dec. 18, 2026 action date.RHHBY's phase III evERA study showed a 44% lower progression risk in ITT and 62% in ESR1-mutated patients.Roche plans more filings as giredestrant advances across five phase III studies in multiple settings.Roche (RHHBY) announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment o ...